Cognitive Behavioral Therapy for Smoking Cessation in HIV/AIDS
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests Cognitive Behavioral Therapy (CBT) to help people with HIV quit smoking. The researchers aim to determine if this therapy can reduce anxiety and depression, which are common in people with HIV and can hinder smoking cessation. Participants will be divided into three groups: one will receive a specialized CBT called QUIT, another will receive a similar but different therapy, and the last group will receive their usual care plus nicotine patches. Individuals who smoke daily, have HIV, and wish to quit smoking may be suitable for this trial. As an unphased trial, this study offers a unique opportunity to explore new methods for improving mental health and aiding smoking cessation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are currently receiving smoking cessation treatment, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Cognitive Behavioral Therapy (CBT) is safe and well-tolerated for helping people with HIV quit smoking. In previous studies, participants handled this therapy well, with no major safety issues reported.
Early results suggest that CBT can significantly increase the chances of quitting smoking. This therapy helps by reducing anxiety and depression, which are common among smokers with HIV.
Although CBT is not a new medication, it has been tested in various groups, including those with HIV, to help people stop smoking. This background provides some confidence in its safety.
The studies reviewed have noted no specific unwanted side effects, highlighting its general safety for participants.12345Why are researchers excited about this trial?
Cognitive Behavioral Therapy for smoking cessation in HIV/AIDS is unique because it combines a psychological approach with smoking cessation specifically tailored for people living with HIV. Most treatments for smoking cessation, like nicotine replacement therapy or prescription medications, focus on reducing withdrawal symptoms. However, this therapy aims to enhance distress tolerance and coping skills, which are crucial for individuals with HIV who often face additional stressors. Researchers are excited because it offers a holistic method, potentially leading to higher success rates in quitting smoking by addressing both the habit and the underlying stress factors.
What evidence suggests that this trial's treatments could be effective for smoking cessation in people living with HIV?
Research has shown that Cognitive Behavioral Therapy (CBT) can help people with HIV quit smoking. In this trial, participants in the QUIT treatment arm will receive a CBT-based intervention for smoking cessation. A previous study found that individuals using the CBT approach were more successful at quitting smoking both in the short term and long term compared to those who received a brief treatment. This therapy reduces anxiety and depression, major challenges for smokers living with HIV. It addresses emotional issues such as excessive fear of anxiety, difficulty coping with emotional discomfort, and trouble experiencing pleasure. These early findings suggest that CBT could effectively help people with HIV stop smoking.13467
Who Is on the Research Team?
Michael Zvolensky, PhD
Principal Investigator
University of Houston
Jasper Smits, PhD
Principal Investigator
University of Texas at Austin
Are You a Good Fit for This Trial?
This trial is for HIV-positive individuals aged 18-79 who smoke daily and are motivated to quit. They must understand English well enough to give informed consent. People using other tobacco products, undergoing current smoking cessation treatment, or with untreated/unstable psychiatric disorders can't participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 9-session, cognitive-behavioral therapy-based intervention for smoking cessation and anxiety/depression management
Short-Term Follow-up
Participants are monitored for smoking abstinence and changes in anxiety/depression at 1-month post quit day
Long-Term Follow-up
Participants are monitored for smoking abstinence and changes in anxiety/depression at 6-months post quit day
What Are the Treatments Tested in This Trial?
Interventions
- QUIT
- Time-Matched Control (TM)
Trial Overview
The study tests a cognitive-behavioral-based intervention called QUIT against a Time-Matched Control (TM) to help smokers living with HIV quit by reducing anxiety and depression. It's a fully powered trial aiming to see if the intervention increases abstinence from smoking at 1-month and 6-month follow-ups.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Southern Methodist University
Collaborator
The Fenway Institute
Collaborator
University of Texas at Austin
Collaborator
University of Houston
Collaborator
Baylor College of Medicine
Collaborator
Citations
Smoking Cessation for People Living With HIV/AIDS
People living with HIV/AIDS (PLWHA) are more likely to smoke cigarettes than are individuals in the general population.
NCT03904186 | Effectiveness of an Integrated Treatment to ...
Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
Efficacy of Smoking Cessation Interventions among People ...
Results ; Years since diagnosed with HIV status, mean (SD), 8.4 (6.1), 7.5 (5.7) ; Prior diagnosis of AIDS, 29 (10.2%), 6 (8.7%) ; Taking ...
Evaluation of an integrated treatment to address smoking ...
AIDS Behav. (2017). D.J. Vidrine et al. Efficacy of cell phone–delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes ...
5.
withpower.com
withpower.com/trial/cognitive-behavioral-therapy-for-smoking-cessation-in-hivaids-f5b72Cognitive Behavioral Therapy for Smoking Cessation in ...
Cognitive Behavioral Therapy for Smoking Cessation in HIV/AIDS. Recruiting at 2 trial locations. CM.
Smoking Cessation Intervention for Women Living With HIV ...
This study is a pilot randomized controlled trial (RCT) testing the feasibility and acceptability of a videoconferencing smoking cessation intervention (video ...
Effect of cognitive behavior therapy on abstinence among ...
The pooled analysis revealed that CBT significantly improved smoking abstinence rates, demonstrating a fourfold increase in effectiveness compared to controls ( ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.